Biohaven Ltd. Common Shares (BHVN) analyst actions
Rating and price-target actions on BHVN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the BHVN overview →
2 measured BHVN analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biohaven Ltd. (BHVN) And Encourages Stockholders to Reach Out | Press release | +0.75% | +0.75% | |
| Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine | Press release | +1.11% | -0.93% |
Keep exploring
More BHVN: earnings → · SEC filings → · BHVN overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Geron Corporation (GERN) | 949 | -0.28% | 41% |
| Intellia Therapeutics, Inc. (NTLA) | 948 | -0.24% | 45% |
| GW PHARMACEUTICALS PLC AMERICA (GWPH) | 942 | -0.06% | 47% |
| Intersect ENT, Inc. (XENT) | 937 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.